Semler Scientific, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 01, 2021 at 04:09 pm EDT
Share
Semler Scientific, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 13.99 million compared to USD 10.73 million a year ago. Net income was USD 4.15 million compared to USD 4.87 million a year ago. Basic earnings per share from continuing operations was USD 0.61 compared to USD 0.74 a year ago. Diluted earnings per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago.
For the nine months, sales was USD 41.49 million compared to USD 26.53 million a year ago. Net income was USD 15.72 million compared to USD 8.61 million a year ago. Basic earnings per share from continuing operations was USD 2.34 compared to USD 1.31 a year ago. Diluted earnings per share from continuing operations was USD 1.93 compared to USD 1.07 a year ago.
Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patientâs vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.
SEMLER SCIENTIFIC, INC. 
